Side-by-side comparison of AI visibility scores, market position, and capabilities
Mumbai smartphone-based diagnostic platform with color-change test cards for UTI, diabetes, and kidney tests for 4K+ doctors; YC S21 $2.48M Omidyar Network-backed with Cipla/Sun Pharma/AstraZeneca partnerships for India at-home diagnostics.
Neodocs is a Mumbai, India-based healthtech company — backed by Y Combinator (S21) with $2.48 million raised including a $2 million seed round in February 2024 led by Omidyar Network India with YC, 9Unicorns, Gemba Capital, Titan Capital, and 100Unicorns — providing instant at-home diagnostic test kits with proprietary biochemistry test cards that deliver visual color-change results for conditions including urinary tract infections, diabetes monitoring (HbA1c and glucose), kidney function (creatinine, protein), and general wellness panels without requiring any additional hardware beyond a smartphone camera. Founded in 2020, Neodocs has sold 200,000+ test cards used by 4,000+ doctors across India and has partnerships with major pharmaceutical companies including Cipla, Sun Pharma, and AstraZeneca for co-branded diagnostic test distribution.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.